Español
Questions About Cancer? 1-800-4-CANCER
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Clinical Trials (PDQ®)

Cisplatin and Radiation Therapy With or Without Carboplatin and Paclitaxel in Patients With Locally Advanced Cervical Cancer

Basic Trial Information
Trial Description
     Summary
     Further Trial Information
     Eligibility Criteria
Trial Contact Information

Basic Trial Information

PhaseTypeStatusAgeSponsorProtocol IDs
Phase IIISupportive care, TreatmentActive18 and overNCI, OtherANZGOG-0902/GOG-0274/RTOG-1174
NCI-2011-02978, CDR0000706698, GOG-0274, RTOG-1174, ANZGOG-0902, ANZGOG-0902-GOG-0274, U10CA027469, NCT01414608

Trial Description

Summary

This randomized phase III trial studies how well giving cisplatin and radiation therapy together with or without carboplatin and paclitaxel works in treating patients with locally advanced cervical cancer. Drugs used in chemotherapy, such as cisplatin, carboplatin, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. External radiation therapy uses high-energy x rays to kill tumor cells. Internal radiation uses radioactive material placed directly into or near a tumor to kill tumor cells. It is not yet known whether giving cisplatin and external and internal radiation therapy together with carboplatin and paclitaxel kills more tumor cells.

Further Study Information

PRIMARY OBJECTIVES:

I. To determine if the addition of adjuvant chemotherapy to standard cisplatin-based chemoradiation improves overall survival.

SECONDARY OBJECTIVES:

I. To determine the progression-free survival rates. II. To determine acute and long-term toxicities. III. To determine patterns of disease recurrence. IV. To determine the association between radiation protocol compliance and outcomes.

V. To determine patient quality of life, including psycho-sexual health.

TERTIARY OBJECTIVES:

I. To determine the association between the results of a follow-up positron emission tomography (PET) scan performed 4-6 months post completion of chemoradiation and outcomes for all patients in the trial.

II. To determine the biological predictors of patients' outcomes based on translational laboratory studies of blood and tissue specimens.

OUTLINE: This is a multicenter study. Patients are stratified according to pelvic or common iliac nodal involvement (yes vs no), requirement for extended-field radiotherapy treatment (yes vs no), International Federation of Gynecology and Obstetrics (FIGO) stage (IB/IIA vs IIB vs IIIB/IVA), age (< 60 years of age vs >= 60 years of age), and hospital/site. Patients are randomized to 1 of 2 treatment arms.

ARM I: Patients receive cisplatin intravenously (IV) over 60-90 minutes on days 1, 8, 15, 22, and 29. Patients also undergo external-beam radiation therapy once daily, 5 days a week, for approximately 5 weeks. Patients then undergo high-dose rate, pulsed-dose rate, or low-dose rate intracavitary brachytherapy.

ARM II: Patients receive cisplatin and undergo external-beam radiation and brachytherapy as in arm I. Beginning 4 weeks later, patients also receive adjuvant chemotherapy comprising paclitaxel IV over 3 hours and carboplatin IV over 1 hour on day 1. Treatment repeats every 21 days for 4 courses in the absence of disease progression or unacceptable toxicity.

Patients may undergo baseline tumor biopsy and blood collection for future correlative studies.

Patients complete the European Organization for Research and Treatment of Cancer (EORTC) Core questionnaire (QLQ-C30), the EORTC cervix cancer module (CX24), the ovarian cancer module (OV28), and the Sexual function-Vaginal Changes Questionnaire (SVQ) questionnaires at baseline, during, and after completion of study treatment.

After completion of study therapy, patients are followed up every 3 months for 2 years and then every 6 months for 3 years.

Eligibility Criteria

Inclusion Criteria:

  • Eligible patients will have locally advanced cervical cancer suitable for primary treatment with chemoradiation with curative intent, in addition to:
  • Histological diagnosis of squamous cell carcinoma, adenocarcinoma, or adenosquamous cell carcinoma of the cervix
  • FIGO 2008 stage IB1 & node positive, IB2, II, IIIB, or IVA disease
  • Eastern Cooperative Oncology Group (ECOG) performance status 0-2
  • Histological diagnosis of squamous cell carcinoma, adenocarcinoma or adenosquamous cell carcinoma of the cervix
  • White blood cells (WBC) >= 3.0 x 10^9/L
  • Absolute neutrophil count (ANC) >= 1.5 x 10^9/L
  • Platelet count >= 100 x 10^9/L
  • Bilirubin =< 1.5 times upper limit of normal (ULN)
  • Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) =< 2.5 x ULN
  • Creatinine =< ULN (Common Toxicity Criteria [CTC] Grade 0) OR calculated creatinine clearance (Cockcroft-Gault Formula) >= 60 mL/min OR >= 50 mL/min by ethylenediaminetetraacetic acid (EDTA) creatinine clearance
  • Written informed consent

Exclusion Criteria:

  • Any previous pelvic radiotherapy
  • Para-aortic nodal involvement above the level of the common iliac nodes or L3/L4 (if biopsy proven, PET positive, or >= 15 mm short-axis diameter on computed tomography [CT])
  • FIGO 2008 stage IIIA disease
  • Patients assessed at presentation as requiring interstitial brachytherapy treatment
  • Patients with bilateral hydronephrosis unless at least one side has been stented and renal function fulfills the required inclusion criteria
  • Previous chemotherapy for this tumor
  • Evidence of distant metastases
  • Prior diagnosis of Crohn disease or ulcerative colitis
  • Peripheral neuropathy >= grade 2 (per Common Terminology Criteria for Adverse Events [CTCAE] v. 4)
  • Patients who have undergone a previous hysterectomy or will have a hysterectomy as part of their initial cervical cancer therapy
  • Patients with other invasive malignancies, with the exception of non-melanoma skin cancer and in situ melanoma, who had (or have) any evidence of the other cancer present within the last 5 years
  • Patients who are pregnant or lactating
  • Any contraindication to the use of cisplatin, carboplatin, or paclitaxel chemotherapy
  • Serious illness or medical condition that precludes the safe administration of the trial treatment including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements
  • Human immunodeficiency virus (HIV) positive

Trial Contact Information

Trial Lead Organizations/Sponsors

Gynecologic Oncology Group

National Cancer Institute

Kathleen MoorePrincipal Investigator

Trial Sites

U.S.A.
Alabama
  Birmingham
 UAB Comprehensive Cancer Center
 Warner Huh Ph: 205-934-0309
  Mobile
 University of South Alabama Mitchell Cancer Institute
 Rodney P Rocconi Ph: 251-445-9870
  Email: pfrancisco@usouthal.edu
Arizona
  Phoenix
 Arizona Oncology Associates - Biltmore Cancer Center
 Michael G Teneriello Ph: 512-427-9400
 GOG of Arizona, PC
 Kathleen N Moore Ph: 405-271-8707
  Email: lreese@gog.org
 St. Joseph's Hospital and Medical Center
 John H Farley Ph: 877-602-4111
Arkansas
  Little Rock
 Arkansas Cancer Research Center at University of Arkansas for Medical Sciences
 Kristin K Zorn Ph: 501-686-8274
California
  Concord
 Cancer Care Center at John Muir Health - Concord Campus
 Babak Edraki Ph: 925-674-2580
  Fremont
 Kaiser Permanente - Fremont
 Tatjana Kolevska Ph: 626-564-3455
  Mountain View
 Palo Alto Medical Foundation
 John K Chan Ph: 415-209-2686
  Email: bernicl@sutterhealth.org
  Orange
 Chao Family Comprehensive Cancer Center at University of California Irvine Medical Center
 Krishnansu S Tewari Ph: 714-456-6191
  Email: awallick@uci.edu
 St. Joseph Hospital Regional Cancer Center - Orange
 Michael L Berman Ph: 877-827-8839
  Email: ucstudy@uci.edu
  Roseville
 Kaiser Permanente Medical Center - Roseville
 Tatjana Kolevska Ph: 626-564-3455
  Sacramento
 University of California Davis Cancer Center
 Gary Leiserowitz Ph: 916-734-3089
  Sylmar
 Olive View - UCLA Medical Center Foundation
 Christine Holschneider Ph: 888-798-0719
  Vallejo
 Kaiser Permanente Medical Center - Vallejo
 Tatjana Kolevska Ph: 626-564-3455
  Walnut Creek
 John Muir/Mt. Diablo Comprehensive Cancer Center
 Babak Edraki Ph: 925-674-2580
Colorado
  Aurora
 University of Colorado Cancer Center at UC Health Sciences Center
 Susan Davidson Ph: 720-848-0650
  Denver
 CCOP - Colorado Cancer Research Program
 Keren Sturtz Ph: 888-785-6789
Connecticut
  Farmington
 Carole and Ray Neag Comprehensive Cancer Center at the University of Connecticut Health Center
 Angela S Kueck Ph: 800-579-7822
  Hartford
 Helen and Harry Gray Cancer Center at Hartford Hospital
 James S. Hoffman Ph: 860-224-5660
  New Britain
 George Bray Cancer Center at the Hospital of Central Connecticut - New Britain Campus
 James S. Hoffman Ph: 860-224-5660
  New Haven
 Yale Cancer Center
 Peter E. Schwartz Ph: 203-785-5702
Delaware
  Newark
 Helen F. Graham Cancer Center at Christiana Hospital
 Mark E Borowsky Ph: 302-733-6227
Florida
  Miami
 University of Miami Sylvester Comprehensive Cancer Center - Miami
 Aaron H Wolfson Ph: 866-574-5124
  Email: Sylvester@emergingmed.com
  Orlando
 M.D. Anderson Cancer Center at Orlando
 Kathleen N Moore Ph: 405-271-4272
  Email: julie-traylor@ouhsc.edu
  Sarasota
 Sarasota Memorial Hospital
 James V. Fiorica Ph: 941-917-2225
Georgia
  Atlanta
 Georgia Cancer Center for Excellence at Grady Memorial Hospital
 Joseph W Shelton Ph: 404-489-9164
 Northside Hospital Cancer Center
 Sahar E Rosenbaum Ph: 404-303-3355
 Winship Cancer Institute of Emory University
 Joseph W Shelton Ph: 404-489-9164
  Gainesville
 Northeast Georgia Medical Center
 Andrew E Green Ph: 770-219-8800
  Email: cancerpatient.navigator@nghs.com
Hawaii
  Honolulu
 Cancer Research Center of Hawaii
 Michael E. Carney Ph: 808-983-6090
 Kaiser Permanente - Moanalua Medical Center and Clinic
 Tatjana Kolevska Ph: 626-564-3455
 MBCCOP - Hawaii
 Michael E. Carney Ph: 808-983-6090
Illinois
  Chicago
 John H. Stroger, Jr. Hospital of Cook County
 Thomas E. Lad Ph: 312-864-6000
 Robert H. Lurie Comprehensive Cancer Center at Northwestern University
 Eric D Donnelly Ph: 312-695-1301
  Email: cancer@northwestern.edu
 University of Chicago Cancer Research Center
 Meaghan E Tenney Ph: 773-834-7424
  Hinsdale
 Gynecologic Oncology
 Sudarshan K. Sharma Ph: 630-856-6757
Indiana
  Elkhart
 Michiana Hematology-Oncology, PC - Elkhart
 Kathleen N Moore Ph: 405-271-4272
  Email: julie-traylor@ouhsc.edu
  Indianapolis
 Indiana University Melvin and Bren Simon Cancer Center
 Jeanne M Schilder Ph: 317-274-2552
 St. Vincent Oncology Center
 Gregory P. Sutton Ph: 317-338-2194
  Mishawaka
 Saint Joseph's Medical Center
 Kathleen N Moore Ph: 405-271-4272
  Email: julie-traylor@ouhsc.edu
Kansas
  Kansas City
 Kansas Masonic Cancer Research Institute at the University of Kansas Medical Center
 Julia A. Chapman Ph: 913-588-4709
Kentucky
  Lexington
 Central Baptist Hospital
 Hope M Cottrill Ph: 859-260-6425
 University of Kentucky Chandler Medical Center
 Frederick Ueland Ph: 859-257-3379
  Louisville
 Louisville Oncology at Norton Cancer Institute - Louisville
 Mary E Gordinier Ph: 502-629-2500
Louisiana
  New Orleans
 Ochsner Cancer Institute at Ochsner Clinic Foundation
 Richard C. Kline Ph: 888-562-4763
 Stanley S. Scott Cancer Center at Louisiana State University Medical Center - New Orleans
 Augusto C Ochoa Ph: 504-568-2428
  Email: emede1@lsuhsc.edu
 Tulane Cancer Center at Tulane University Hospital and Clinic
 William R. Robinson Ph: 504-988-6121
Maine
  Portland
 Maine Medical Center - Bramhall Campus
 Christopher J Darus Ph: 207-885-7565
Maryland
  Baltimore
 Greenebaum Cancer Center at University of Maryland Medical Center
 Gautam G Rao Ph: 800-888-8823
  Bethesda
 National Naval Medical Center
 Michael P Stany Ph: 301-319-2100
Massachusetts
  Springfield
 Baystate Medical Center
 Tashanna K Myers Ph: 413-794-3565
  Email: tamara.wrenn@baystatehealth.org
  Worcester
 Levine Cancer Center at UMass Medical Center - Memorial Campus
 Susan L. Zweizig Ph: 508-856-3216
  Email: cancer.research@umassmed.edu
Michigan
  Battle Creek
 Battle Creek Health System Cancer Care Center
 Gilbert D Padula Ph: 616-685-5225
  Email: connie.szczepanek@grcop.org
  Detroit
 Josephine Ford Cancer Center at Henry Ford Hospital
 Thomas E Buekers Ph: 313-916-1784
 Wayne State University
 Robert T. Morris Ph: 313-576-9363
  Grand Rapids
 Butterworth Hospital at Spectrum Health
 Gilbert D Padula Ph: 616-685-5225
  Email: connie.szczepanek@grcop.org
 Lacks Cancer Center at Saint Mary's Health Care
 Gilbert D Padula Ph: 616-685-5225
  Email: connie.szczepanek@grcop.org
  Kalamazoo
 West Michigan Cancer Center
 Sunil Nagpal Ph: 269-373-7458
  Royal Oak
 William Beaumont Hospital - Royal Oak Campus
 Jayson B Field Ph: 248-551-7695
  Traverse City
 Munson Medical Center
 Gilbert D Padula Ph: 616-685-5225
  Email: connie.szczepanek@grcop.org
Minnesota
  Edina
 Fairview Southdale Hospital
 Daniel M Anderson Ph: 952-993-1517
  Email: MMCCOP@parknicollet.com
  Minneapolis
 Masonic Cancer Center at University of Minnesota
 Peter A Argenta Ph: 612-624-2620
  Woodbury
 Minnesota Oncology - Woodbury
 Matthew P Boente Ph: 952-993-1517
  Email: MMCCOP@parknicollet.com
Mississippi
  Jackson
 University of Mississippi Cancer Clinic
 James Tate Thigpen Ph: 601-815-6700
Missouri
  Springfield
 Hulston Cancer Center at Cox Medical Center South
 Jay W Carlson Ph: 800-821-7532
 St. John's Regional Health Center
 Jay W Carlson Ph: 800-821-7532
Nebraska
  Omaha
 Fred and Pamela Buffett Cancer Center
 Kerry Rodabaugh Ph: 800-999-5465
 Methodist Estabrook Cancer Center
 Peter C. Morris Ph: 402-354-7939
  Email: kathryn.bartz@nmhs.org
Nevada
  Las Vegas
 Women's Cancer Center - La Canada
 Nick M. Spirtos Ph: 702-851-4672
New Jersey
  Camden
 Cancer Institute of New Jersey at Cooper University Hospital - Camden
 David P. Warshal Ph: 856-325-6757
  Hackensack
 Hackensack University Medical Center Cancer Center
 Donna T McNamara Ph: 201-996-2879
  Morristown
 Carol G. Simon Cancer Center at Morristown Memorial Hospital
 Yana P Goldberg Ph: 973-971-5900
New Mexico
  Albuquerque
 University of New Mexico Cancer Center
 Kathleen N Moore Ph: 405-271-4272
  Email: julie-traylor@ouhsc.edu
New York
  Albany
 Women's Cancer Care Associates
 Thomas P Morrissey Ph: 518-458-1390
  Bronx
 Albert Einstein Cancer Center at Albert Einstein College of Medicine
 Mark H. Einstein Ph: 718-904-2730
  Email: aecc@aecom.yu.edu
  Brooklyn
 SUNY Downstate Medical Center
 Ovadia Abulafia Ph: 718-270-8216
  Email: sima.terebelo@downstate.edu
  Buffalo
 Roswell Park Cancer Institute
 Peter J Frederick Ph: 877-275-7724
  Manhasset
 Don Monti Comprehensive Cancer Center at North Shore University Hospital
 Veena S John Ph: 516-562-3467
  Mineola
 Winthrop University Hospital
 Jeannine A Villella Ph: 866-946-8476
  New Hyde Park
 Long Island Jewish Medical Center
 Veena S John Ph: 516-562-3467
 Monter Cancer Center of the North Shore-LIJ Health System
 Veena S John Ph: 516-562-3467
  New York
 Memorial Sloan-Kettering Cancer Center
 Mario M Leitao Ph: 212-639-7202
 New York University Medical Center
 Stephanie V. Blank Ph: 212-263-4434
  Email: prmc.coordinator@nyumc.org
  Stony Brook
 Stony Brook University Cancer Center
 Michael L. Pearl Ph: 800-862-2215
North Carolina
  Burlington
 Alamance Cancer Center at Alamance Regional Medical Center
 Janak K. Choksi Ph: 336-538-7725
  Charlotte
 Blumenthal Cancer Center at Carolinas Medical Center
 Robert Victor Higgins Ph: 704-355-2884
  Concord
 Batte Cancer Center at Northeast Medical Center
 Brigitte E. Miller Ph: 704-403-1520
Ohio
  Akron
 Summa Center for Cancer Care at Akron City Hospital
 Vivian von Gruenigen Ph: 330-375-6101
  Cleveland
 Cleveland Clinic Cancer Center at Fairview Hospital
 Peter Graham Rose Ph: 866-223-8100
 Cleveland Clinic Taussig Cancer Center
 Peter Graham Rose Ph: 866-223-8100
 MetroHealth Cancer Care Center at MetroHealth Medical Center
 Peter Graham Rose Ph: 866-223-8100
  Columbus
 Arthur G. James Cancer Hospital and Richard J. Solove Research Institute at Ohio State University Comprehensive Cancer Center
 David M O'Malley Ph: 800-293-5066
  Email: Jamesline@osumc.edu
  Dayton
 David L. Rike Cancer Center at Miami Valley Hospital
 Howard M. Gross Ph: 937-775-1350
  Kettering
 Charles F. Kettering Memorial Hospital
 Howard M. Gross Ph: 937-775-1350
  Mayfield Heights
 Hillcrest Cancer Center at Hillcrest Hospital
 Peter Graham Rose Ph: 866-223-8100
  Toledo
 University of Toledo Medical Center
 Rex B Mowat Ph: 517-265-0116
Oklahoma
  Oklahoma City
 Oklahoma University Cancer Institute
 Robert S. Mannel Ph: 405-271-4272
  Email: julie-traylor@ouhsc.edu
  Tulsa
 Cancer Care Associates-Yale
 Robert S. Mannel Ph: 405-271-4272
  Email: julie-traylor@ouhsc.edu
Pennsylvania
  Abington
 Rosenfeld Cancer Center at Abington Memorial Hospital
 Parviz Hanjani Ph: 215-481-2402
  Bethlehem
 St. Luke's Cancer Network at St. Luke's Hospital
 Nicholas P Taylor Ph: 610-954-3582
  Email: infolink@slhn.org
  Philadelphia
 Abramson Cancer Center of the University of Pennsylvania
 Robert A. Burger Ph: 215-746-7406
 Gynecologic Oncology Group
 Philip J. DiSaia Ph: 215-854-0770
  Email: lreese@gog.org
 Kimmel Cancer Center at Thomas Jefferson University - Philadelphia
 Pramila Rani Anne Ph: 215-955-6084
  Pittsburgh
 UPMC - Shadyside
 Dwight E Heron Ph: 412-647-8073
 UPMC Cancer Center at Magee-Womens Hospital
 Dwight E Heron Ph: 412-647-8073
  West Reading
 McGlinn Family Regional Cancer Center at Reading Hospital and Medical Center
 Bernice L Robinson-Bennett Ph: 610-988-9323
Rhode Island
  Providence
 Women and Infants Hospital of Rhode Island
 Paul A. DiSilvestro Ph: 401-274-1122
South Carolina
  Anderson
 AnMed Cancer Center
 David Griffin Ph: 864-512-1000
  Charleston
 Hollings Cancer Center at Medical University of South Carolina
 Jennifer L Young Pierce Ph: 843-792-9321
  Greenville
 Bon Secours St. Francis Health System
 David Griffin Ph: 864-512-1000
  Spartanburg
 Gibbs Regional Cancer Center at Spartanburg Regional Medical Center
 David Griffin Ph: 864-512-1000
South Dakota
  Rapid City
 Black Hills Obstetrics & Gynecology LLP
 Helen L. Frederickson Ph: 605-343-9224
 Rapid City Regional Hospital
 Helen L. Frederickson Ph: 605-343-9224
Texas
  Austin
 Texas Oncology - Midtown Austin
 Michael G Teneriello Ph: 512-427-9400
 Texas Oncology, PA at South Austin Cancer Center
 Michael G Teneriello Ph: 512-427-9400
 Texas Oncology, PA at Texas Oncology Cancer Center - Central
 Michael G Teneriello Ph: 512-427-9400
  Bedford
 Texas Oncology, PA at Harris Center HEB
 Michael G Teneriello Ph: 512-427-9400
  Dallas
 Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas
 David Scott Miller Ph: 214-648-7097
  Fort Worth
 Texas Oncology, PA - Fort Worth
 Michael G Teneriello Ph: 512-427-9400
  Houston
 Lyndon B. Johnson General Hospital
 Lois M. Ramondetta Ph: 713-792-3245
 M. D. Anderson Cancer Center at University of Texas
 Lois M. Ramondetta
  Email: lramonde@mdanderson.org
 Memorial Hermann - Texas Medical Center
 Anthony Lucci Ph: 866-574-5124
  Email: Sylvester@emergingmed.com
Utah
  Murray
 Jon and Karen Huntsman Cancer Center at Intermountain Medical Center
 R. Jeffrey Lee Ph: 801-507-3950
  Saint George
 Dixie Regional Medical Center - East Campus
 R. Jeffrey Lee Ph: 801-507-3950
  Salt Lake City
 Huntsman Cancer Institute at University of Utah
 Matthew M Poppe Ph: 801-581-4477
  Email: clinical.trials@hci.utah.edu
 LDS Hospital
 R. Jeffrey Lee Ph: 801-507-3950
 Utah Cancer Specialists at UCS Cancer Center
 R. Jeffrey Lee Ph: 801-507-3950
Virginia
  Charlottesville
 University of Virginia Cancer Center
 Susan C Modesitt Ph: 434-243-6143
  Richmond
 Virginia Commonwealth University Massey Cancer Center
 Weldon E Chafe Ph: 804-628-1939
  Roanoke
 Carilion Clinic Gynecological Oncology
 Janet L. Osborne Ph: 540-985-8510
Wisconsin
  Green Bay
 Vince Lombardi Cancer Clinic - Green Bay at Aurora BayCare Medical Center
 Ali Mahdavi Ph: 414-649-5717
  Madison
 University of Wisconsin Paul P. Carbone Comprehensive Cancer Center
 Kristin Ann Bradley Ph: 877-405-6866
  Milwaukee
 Froedtert Hospital and Medical College of Wisconsin
 William H Bradley Ph: 414-805-4380
 Vince Lombardi Cancer Clinic at Aurora St. Luke's Medical Center
 Ali Mahdavi Ph: 414-649-5717
  Oshkosh
 Vince Lombardi Cancer Clinic - Oshkosh
 Ali Mahdavi Ph: 414-649-5717
Canada
Ontario
  Hamilton
 Margaret and Charles Juravinski Cancer Centre
 Lorraine (Laurie) M Elit Ph: 905-387-9495
  London
 London Regional Cancer Program at London Health Sciences Centre
 David P. D'Souza Ph: 519-685-8600
  Toronto
 Princess Margaret Hospital
 Anthony W Fyles Ph: 416-946-4501
  Email: clinical.trials@uhn.on.ca
Quebec
  Montreal
 Hopital Notre-Dame du CHUM
 Maroie Barkati Ph: 514-890-8000ext23611
  Email: sylvie.beaudoin.chum@ssss.gouv.qc.ca
Saskatchewan
  Regina
 Allan Blair Cancer Centre at Pasqua Hospital
 Evgeny Sadikov Ph: 306-766-2213

Link to the current ClinicalTrials.gov record.
NLM Identifer NCT01414608
ClinicalTrials.gov processed this data on December 23, 2014

Note: Information about this trial is from the ClinicalTrials.gov database. The versions designated for health professionals and patients contain the same text. Minor changes may be made to the ClinicalTrials.gov record to standardize the names of study sponsors, sites, and contacts. Cancer.gov only lists sites that are recruiting patients for active trials, whereas ClinicalTrials.gov lists all sites for all trials. Questions and comments regarding the presented information should be directed to ClinicalTrials.gov.

Back to TopBack to Top